FDA approves first treatment for all genotypes of hepatitis C in pediatric patients

FDA approves first treatment for all genotypes of hepatitis C in pediatric patients 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-all-genotypes-hepatitis-c-pediatric-patients?utm_campaign=04302019_PR_FDA+approves+first+treatment+for+all+genotypes+of+hepatitis+C+in+children&utm_medium=email&utm_source=Eloqua

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. Mavyret was previously approved to treat HCV in adults in 2017. “Direct-acting antiviral drugs reduce the amount of HCV in the body by preventing the virus from multiplying, and in most cases...

Read More